Want to see CGON full AI Analyst Report?
CG Oncology, Inc. (CGON) Ratios
CG Oncology, Inc. Ratios
CGON's free cash flow for Q2 2026 was $-46.88M. For the 2026 fiscal year, CGON's free cash flow was decreased by $-468.00K and operating cash flow was $-46.41M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 24.63 | 35.30 | 13.62 | 9.54 | 9.78 |
| Quick Ratio | 24.58 | 35.30 | 13.62 | 9.54 | 9.78 |
| Cash Ratio | 1.05 | 12.03 | 0.58 | 5.71 | 8.97 |
| Solvency Ratio | -4.09 | -4.11 | -3.35 | -1.57 | -0.70 |
| Operating Cash Flow Ratio | -4.29 | -3.68 | -3.20 | -1.93 | -2.29 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | -80.28 | -3.32 | -4.64 |
| Net Current Asset Value | $ 720.49M | $ 732.79M | $ 179.61M | $ 124.64M | $ 39.97M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.01 | 0.00 | 0.01 | 0.11 | 0.26 |
| Debt-to-Equity Ratio | 0.01 | 0.00 | 0.01 | 0.13 | 0.38 |
| Debt-to-Capital Ratio | 0.01 | 0.00 | 0.01 | 0.11 | 0.27 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.05 | 0.23 |
| Financial Leverage Ratio | 1.05 | 1.03 | 1.08 | 1.18 | 1.46 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | -97.42 | -3.93 | -3.65 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | -35246.00 | -27.95 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 |
| Interest Debt Per Share | 0.09 | 0.00 | 0.02 | 0.24 | 0.23 |
| Net Debt to EBITDA | 0.16 | 2.92 | 0.13 | 2.05 | 3.11 |
| Profitability Margins | |||||
| Gross Profit Margin | -15.02% | 100.00% | 100.00% | 92.15% | 99.90% |
| EBIT Margin | -3985.02% | -7729.50% | -27180.88% | -18453.40% | -119.60% |
| EBITDA Margin | -3949.26% | -7726.69% | -27172.55% | -18445.55% | -119.50% |
| Operating Profit Margin | -4722.13% | -10067.25% | -27180.88% | -18453.40% | -121.70% |
| Pretax Profit Margin | -3985.02% | -7729.50% | -23826.96% | -18556.54% | -123.95% |
| Net Profit Margin | -3985.02% | -7729.50% | -23826.96% | -18556.54% | -123.95% |
| Continuous Operations Profit Margin | -3985.02% | -7729.50% | -23826.96% | -18556.54% | -123.95% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 84.39% | 76.78% | 87.66% | 100.56% | 101.85% |
| Return on Assets (ROA) | -20.34% | -11.66% | -24.39% | -23.99% | -21.88% |
| Return on Equity (ROE) | -21.39% | -12.00% | -26.30% | -28.31% | -31.90% |
| Return on Capital Employed (ROCE) | -25.08% | -15.63% | -29.96% | -26.64% | -23.91% |
| Return on Invested Capital (ROIC) | -25.05% | -15.63% | -29.84% | -24.91% | -22.62% |
| Return on Tangible Assets | -20.62% | -11.66% | -24.39% | -23.99% | -21.88% |
| Earnings Yield | -5.02% | -4.91% | -1.96% | -1.43% | -0.52% |
| Efficiency Ratios | |||||
| Receivables Turnover | 5.87 | 1.46 | 2.22 | 0.63 | 5179.00 |
| Payables Turnover | 0.81 | 0.00 | 0.00 | 0.02 | 0.01 |
| Inventory Turnover | 2.97 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.21 | 2.31 | 0.42 | 0.38 | 51.79 |
| Asset Turnover | 0.01 | 0.00 | 0.00 | 0.00 | 0.18 |
| Working Capital Turnover Ratio | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -263.73 | 250.28 | 164.61 | -23389.30 | -36609.43 |
| Days of Sales Outstanding | 62.16 | 250.28 | 164.61 | 579.03 | 0.07 |
| Days of Inventory Outstanding | 122.92 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 448.81 | 0.00 | 0.00 | 23968.33 | 36609.50 |
| Operating Cycle | 185.08 | 250.28 | 164.61 | 579.03 | 0.07 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.71 | -1.26 | -0.69 | -0.45 | -0.20 |
| Free Cash Flow Per Share | -1.71 | -1.26 | -0.69 | -0.45 | -0.21 |
| Dividend Paid and CapEx Coverage Ratio | -987.66 | -336.38 | 0.00 | -2128.86 | -140.76 |
| Capital Expenditure Coverage Ratio | -987.66 | -336.38 | 0.00 | -2128.86 | -140.76 |
| Operating Cash Flow Coverage Ratio | -18.85 | -330.73 | -44.35 | -1.87 | -0.90 |
| Operating Cash Flow to Sales Ratio | -32.76 | -69.11 | -223.92 | -156.04 | -1.32 |
| Free Cash Flow Yield | -4.13% | -4.40% | -1.84% | -1.20% | -0.56% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -19.96 | -20.36 | -50.96 | -69.88 | -192.92 |
| Price-to-Sales (P/S) Ratio | 794.47 | 1573.67 | 12141.52 | 12967.90 | 239.13 |
| Price-to-Book (P/B) Ratio | 4.26 | 2.44 | 13.40 | 19.79 | 61.53 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -24.23 | -22.70 | -54.22 | -83.07 | -180.12 |
| Price-to-Operating Cash Flow Ratio | -24.25 | -22.77 | -54.22 | -83.11 | -181.40 |
| Price-to-Earnings Growth (PEG) Ratio | -0.42 | -0.53 | -0.93 | -0.51 | 0.00 |
| Enterprise Value Multiple | -19.96 | -17.45 | -44.55 | -68.25 | -196.99 |
| Enterprise Value | 3.18B | 1.54B | 2.47B | 2.40B | 2.44B |
| EV to EBITDA | -19.96 | -17.45 | -44.55 | -68.25 | -196.99 |
| EV to Sales | 788.16 | 1348.18 | 12106.05 | 12589.90 | 235.41 |
| EV to Free Cash Flow | -24.04 | -19.45 | -54.06 | -80.64 | -177.32 |
| EV to Operating Cash Flow | -24.06 | -19.51 | -54.06 | -80.68 | -178.58 |
| Tangible Book Value Per Share | 9.60 | 11.73 | 2.77 | 1.88 | 0.60 |
| Shareholders’ Equity Per Share | 9.74 | 11.73 | 2.77 | 1.88 | 0.60 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.05 | 0.02 | 0.00 | 0.00 | 0.16 |
| Net Income Per Share | -2.08 | -1.41 | -0.73 | -0.53 | -0.19 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 0.88 | 1.01 | 1.04 |
| Research & Development to Revenue | 28.87 | 72.08 | 224.27 | 151.98 | 1.77 |
| SG&A to Revenue | 18.20 | 29.59 | 48.53 | 33.55 | 0.45 |
| Stock-Based Compensation to Revenue | 6.60 | 10.01 | 7.49 | 3.54 | 0.11 |
| Income Quality | 0.82 | 0.89 | 0.94 | 0.84 | 1.06 |
Currency in USD
